Your browser doesn't support javascript.
loading
Mechanisms of secondary resistance to imatinib in gastrointestinal stromal tumors / 国际肿瘤学杂志
Journal of International Oncology ; (12): 936-939, 2010.
Artigo em Chinês | WPRIM | ID: wpr-385637
ABSTRACT
Imatinib is an effective tyrosine kinase inhibitor, used in the treatment of advanced or inoperable gastrointestinal stromal tumors. Despite its efficacy, resistance is often developed among a portion of patients. Resistance to imatinib can be divided into primary and secondary resistance, with the latter becoming the focus of many recent researches. Research on the mechanisms of secondary resistance may lead to the identification of novel therapeutic strategies.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Journal of International Oncology Ano de publicação: 2010 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Journal of International Oncology Ano de publicação: 2010 Tipo de documento: Artigo